Zahger D, Fishbein M C, Garfinkel L I, Shah P K, Forrester J S, Regnstrom J, Yano J, Cercek B
Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Circulation. 1995 Sep 1;92(5):1269-73. doi: 10.1161/01.cir.92.5.1269.
Arterial injury is immediately followed by platelet adhesion at the site of injury, a process that requires the interaction of subendothelial von Willebrand factor with the platelet GP1b receptor. VCL, a recombinant von Willebrand factor GP1b binding domain, inhibits platelet binding to von Willebrand factor. The aim of this study was to determine whether VCL inhibits platelet adhesion at the site of arterial injury and affects neointimal thickening after injury in rats.
Sprague-Dawley rats were randomized to receive VCL, 4 mg/kg bolus followed by a continuous infusion of 2 mg.kg-1.h-1 for 72 hours, or an identical volume of saline. Balloon injury of the femoral artery was performed 15 minutes after the initial bolus injection of VCL. Scanning electron microscopy performed 1 and 3 days after injury indicated that VCL-treated rats had > 80% reduction in the number of platelets adherent to the vessel wall at the site of injury compared with controls (P < .003). Histological examination at day 14 showed that, compared with controls, VCL-treated rats had a 60% reduction in the intima-media ratio (0.21 +/- 0.03 versus 0.53 +/- 0.06, P = .001) and a reduced luminal area stenosis (12 +/- 3% versus 38 +/- 10%, P = .04). At 28 days after injury, there was no rebound of neointimal thickening in VCL-treated rats (intima-media ratio, 0.19 +/- 0.04; luminal stenosis, 17 +/- 5%). The difference between VCL-treated rats and control rats persisted but was attenuated (intima-media ratio, 0.19 +/- 0.04 versus 0.28 +/- 0.1, P = .162; luminal stenosis, 17 +/- 5% versus 31 +/- 5%, P = .058) as neointimal thickening regressed in untreated rats. With the use of proliferating cell nuclear antigen immunohistochemistry on day 3, VCL had no effect on smooth muscle cell (SMC) proliferation.
Antagonism of the platelet GP1b receptor by VCL profoundly decreased platelet deposition at the site of balloon injury in the rat femoral artery. This effect was associated with a persistent reduction in neointimal thickening. The lack of effect of VCL on SMC proliferation suggests that the decrease in neointimal thickening may have been mediated through inhibition of SMC migration and/or modulation of the extracellular matrix.
动脉损伤后紧接着血小板会在损伤部位黏附,这一过程需要内皮下血管性血友病因子与血小板糖蛋白1b(GP1b)受体相互作用。VCL是一种重组的血管性血友病因子GP1b结合结构域,可抑制血小板与血管性血友病因子的结合。本研究的目的是确定VCL是否能抑制大鼠动脉损伤部位的血小板黏附,并影响损伤后的新生内膜增厚。
将Sprague-Dawley大鼠随机分为两组,一组接受VCL,静脉推注4mg/kg,随后以2mg·kg-1·h-1的速度持续输注72小时;另一组接受相同体积的生理盐水。在首次推注VCL后15分钟,对股动脉进行球囊损伤。损伤后1天和3天进行扫描电子显微镜检查,结果显示与对照组相比,接受VCL治疗的大鼠损伤部位血管壁上黏附的血小板数量减少了80%以上(P<0.003)。在第14天进行组织学检查,结果显示与对照组相比,接受VCL治疗的大鼠内膜中膜比降低了60%(0.21±0.03对0.53±0.06,P=0.001),管腔面积狭窄程度降低(12±3%对38±10%,P=0.04)。在损伤后28天,接受VCL治疗的大鼠新生内膜增厚没有反弹(内膜中膜比为0.19±0.04;管腔狭窄为17±5%)。接受VCL治疗的大鼠与对照大鼠之间的差异仍然存在,但随着未治疗大鼠新生内膜增厚的消退,差异有所减弱(内膜中膜比为0.19±0.04对0.28±0.1,P=0.162;管腔狭窄为17±5%对31±5%,P=0.058)。在第3天使用增殖细胞核抗原免疫组织化学方法检测,VCL对平滑肌细胞(SMC)增殖没有影响。
VCL对血小板GP1b受体的拮抗作用显著降低了大鼠股动脉球囊损伤部位的血小板沉积。这种作用与新生内膜增厚的持续减少有关。VCL对SMC增殖无影响,提示新生内膜增厚的减少可能是通过抑制SMC迁移和/或调节细胞外基质介导的。